Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Manish R. Patel(Sarah Cannon), Amir T. Fathi(University of Southern California), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Gail J. Roboz(Cornell University), Stéphane de Botton(Université Paris-Saclay), Anthony S. Stein(University of Hohenheim), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Jessica K. Altman(Northwestern University), Christophe Willekens(Université Paris-Saclay), Daniel A. Pollyea(University of Colorado Denver), Ronan Swords(University of Miami), Robert Knight(King's College London), Alessandra Tosolini, Katharine Yen(Agios Pharmaceuticals (United States)), Mikkael A. Sekeres(University of Miami), Sam Agresta(Agios Pharmaceuticals (United States)), Richard M. Stone(Dana-Farber Cancer Institute), Paresh Vyas(University of Oxford), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Arthur E. Frankel(Cancer Institute of Florida), Robert H. Collins(Texas Oncology), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Bruno C. Medeiros(Stanford Medicine), Qiang Xu(Wannan Medical College), Ian W. Flinn(Tennessee Oncology)
Cited by 1,466
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k